98%
921
2 minutes
20
Background: The syndemic of substance use and human immunodeficiency virus (HIV) is a well-recognized global phenomenon that threatens to undermine the priorities outlined by the National Institutes of Health "Ending the HIV Epidemic" initiative. There are few published studies on preexposure prophylaxis (PrEP) for adolescents and young adults (AYAs) with opioid use disorder (OUD) despite increasing availability of biomedical prevention options and Centers for Disease Control and Prevention recommendations to offer PrEP to this group.
Methods: Healthcare providers who previously prescribed medications for OUD (MOUDs) and/or PrEP for AYA were purposively sampled. Audio-recorded in-depth individual interviews were conducted using chart-stimulated recall to explore barriers and facilitators to integrated MOUD and HIV prevention services. Interviews were double-coded, and qualitative analysis was performed using a modified grounded theory.
Results: Of 19 providers sampled, most were physicians (63%). All recommended HIV screening at varying intervals; however, few counseled on (19%) or prescribed (11%) PrEP to patients on MOUD. Barriers to PrEP prescriptions included patient-level (ie, stigma surrounding PrEP use, adherence challenges, and competing social or mental healthcare needs), provider (perception of low risk, lack of training/experience), and system-level factors (including restricted visit types). Facilitators of PrEP prescriptions included patient-initiated requests, electronic health record system reminders, and the availability of consistent support staff (ie, navigators, certified recovery specialists).
Conclusions: Our study confirms that discussions about HIV prevention and PrEP prescriptions may be rare for AYA patients receiving MOUD. Further research is needed to develop interventions that increase the integration of PrEP delivery within the context of OUD care among this key AYA population.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10740380 | PMC |
http://dx.doi.org/10.1097/ADM.0000000000001195 | DOI Listing |
Can Pharm J (Ott)
August 2025
College of Pharmacy, Faculty of Health, Dalhousie University, Halifax, NS.
Background: Pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) is highly effective at reducing the risk of acquiring HIV. PrEP is underused due, in part, to prescriber inaccessibility. The overall aim of this study was to evaluate the impact of pharmacist PrEP management (including prescribing and monitoring) on clinical and acceptance outcomes in patients who are at high risk for HIV exposure.
View Article and Find Full Text PDFCan J Infect Dis Med Microbiol
August 2025
Division of Nephrology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
In clinical trials, pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate-emtricitabine (TDF/FTC) or tenofovir alafenamide-emtricitabine (TAF/FTC) is up to 99% efficacious in preventing human immunodeficiency virus (HIV) infection. The real-world effectiveness of PrEP has not been extensively evaluated in Canada. This population-based cohort included adults without HIV as determined by viral serology and ICD-9/ICD-10 codes from Alberta with ≥ 3 months of PrEP prescriptions.
View Article and Find Full Text PDFMed Decis Making
August 2025
Department of Health Services, Policy and Practice, Brown University School of Public Health, Providence, RI, USA.
ObjectivesTransgender (trans) people have disproportionately high HIV risk, yet adherence to preexposure prophylaxis (PrEP) remains low in this population. We aimed to determine which factors matter most in the decision of HIV-negative transgender adults to adhere to long-acting injectable PrEP (LA-PrEP), and the acceptability of providing incentives conditional on LA-PrEP program engagement.MethodsFrom March to April 2023, 385 trans adults in Washington State completed a discrete-choice experiment (DCE) eliciting preferences for a conditional economic incentive program that would provide free LA-PrEP and gender-affirming care during bimonthly visits.
View Article and Find Full Text PDFSex Transm Dis
August 2025
Section of Infectious Diseases and Global Health, Department of Medicine, University of Chicago, Chicago, IL 60637, USA.
Background: Pre-exposure prophylaxis (PrEP) are medications that prevent HIV infection. However, PrEP is not equally used by all who would benefit. We examined PrEP disparities by comparing the number of sexually transmitted infections (STIs) and PrEP prescriptions across sex, race, and ethnic groups from two federally qualified health centers (FQHCs) in Pinellas County, Florida and Chicago, Illinois.
View Article and Find Full Text PDFDisaster Med Public Health Prep
August 2025
Department of Community-Based Medical Systems, Graduate School of Biomedical and Health Sciences, https://ror.org/03t78wx29Hiroshima University, Hiroshima, Japan.
Objectives: No study has evaluated the relationship between heavy rain disasters and influenza by comparing victims and non-victims, and we investigated the association between the 2018 western Japan heavy rain disaster and influenza.
Methods: All patients registered in the National Health Insurance Claims Database and treated in the Hiroshima, Okayama, and Ehime prefectures were included in this retrospective cohort study conducted 1-year post-disaster. A multivariate mixed-effects logistic regression analysis was used to assess the association between the disaster and anti-influenza drug prescribing.